Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors.
Ilaria ColomboSofia GentaFederica MartoranaMonia GuidiMilo FrattiniEleftherios Pierre Pierre SamartzisSimone BrandtSheila GaggettaLaura MoserMariarosa PascaleTatiana TerrotCristiana SessaAnastasios StathisPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Gedatolisib combined with carboplatin and paclitaxel is tolerable, and preliminary efficacy was observed especially in CCOC.
Keyphrases